

To: Medical Staff, Nursing Units, and Laboratory Clients

From: Stephen C. Ingels, M.D., Eric Thompson, M.D., Calvin Bohanan, MHA, MLS (AMT)

Subject: Diasorin Liaison XL QuantiFERON TB Gold Plus assay

Date: September 27, 2023

Norman Regional Laboratory Services is pleased to announce that we will now be offering the Diasorin Liaison XL QuantiFERON TB Gold assay in house with an expected Go-Live date of Monday, October 2nd, 2023.

INTENDED USE:

The assay is a qualitative indirect test for *M. tuberculosis* infection (including disease) and is intended for use in conjunction with risk assessment, radiography, and other medical and diagnostic evaluations to assist the clinician in making individual patient management decisions.

INTERPRETATION OF RESULTS:

LIAISON® QuantiFERON® -TB Gold Plus (in Mediatech)	Interpretation
Positive	<i>M. tuberculosis</i> infection likely
Negative	<i>M. tuberculosis</i> infection NOT likely
Indeterminate	Likelihood of <i>M. tuberculosis</i> infection cannot be determined

DISCLAIMER:

Diagnosing or excluding tuberculosis disease, and assessing the probability of LTBI, requires a combination of epidemiological, historical, medical, and diagnostic findings that should be taken into account when interpreting LIAISON QuantiFERON-TB Gold Plus assay results. See general guidance on the diagnosis and treatment of TB disease and LTBI <https://www.cdc.gov/tb/publications/guidelines/default.htm>.

SPECIMEN INFO:

- **Mediatech Test Name:** QFT
- **Specimen Type:** Plasma
- **Container/Tube:** Lithium Heparin (no change from previous specimen type)
- **Volume:** 4 mL (fill light green completely)
- **Transport:** Refrigerated 2-8°C
- **Performance:** Monday-Wednesday-Friday, with an pre-incubation time of 24 hrs, with an expected turnaround time of 2-5 days

For questions about this change, please call Kenneth Dohm (Clinical Lab Manager) at (405) 307-1114, or a pathologist at (405) 307-1141.